Abstract
Potential DDIs and inappropriate medications constitute a burden for people living with HIV in China. The knowledge of DDIs patterns and the scan for DDIs is crucial. Indeed, they can help to prevent drug-related adverse outcomes in such immunodeficient population.
Introduction
As antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition, the clinical focus has shifted toward long-term health maintenance. However, this success introduces the challenge of polypharmacy. People living with HIV (PLWH) increasingly require medications for age-related comorbidities and opportunistic infections, creating a complex landscape of potential drug–drug interactions (DDIs). In the Chinese healthcare context, where prescribing patterns and drug availability differ from Western cohorts, understanding these risks is essential for patient safety.
Methods
This cross-sectional, multi-center study analyzed 600 HIV-positive adults across 20 Chinese provinces. To evaluate DDI risk, researchers utilized the University of Liverpool HIV Drug Interaction Database, which categorizes interactions using a "traffic light" system:
- Red-flag: Contraindicated (avoid combination).
- Orange-flag: Potential interaction requiring dosage adjustment or monitoring.
- Yellow-flag: Weak clinical significance.
- Green-flag: No anticipated interaction.
Multivariable logistic regression was employed to identify independent predictors of clinically significant (Red or Orange) DDIs.
Key Results
The study identified a total of 2,566 potential interactions among the 600 participants. While the majority of interactions were classified as "Green-flag," a significant portion required clinical attention.
Specifically, 0.43% of interactions were strictly contraindicated (Red-flag), and 12.89% were clinically relevant (Orange-flag). The primary drivers of these risks included:
- Boosted Regimens: The use of Protease Inhibitors (PIs) or Integrase Strand Transfer Inhibitors (INSTIs) combined with pharmacokinetic boosters (like ritonavir) increased the risk of significant DDIs by 27 and 13.7 times, respectively.
- Systemic Antiinfectives: Antibiotics and antifungals accounted for over 53% of co-medications and were involved in most Red-flag interactions, particularly those involving rifampicin.
- The Hypertension Paradox: Patients with hypertension showed a reduced risk of DDIs (aOR 0.54), likely due to more cautious prescribing or the use of safer antihypertensive classes.
Discussion and Conclusion
The high prevalence of co-medication (85.2%) among PLWH in China underscores the need for integrated primary care. The "booster penalty" remains a significant concern, as drugs intended to maintain ARV levels often inadvertently elevate the toxicity of other medications.
While this study provides a vital snapshot, it is limited by the potential underreporting of over-the-counter and herbal supplements, which are common in China. Furthermore, the findings represent potential rather than observed clinical outcomes. Future efforts should focus on integrating automated DDI screening tools into electronic medical record systems to provide real-time alerts for clinicians, ultimately reducing the burden of inappropriate medication in this vulnerable population.
Summary updated